We kind of have to wait and watch
Each year, as winter approaches the Southern Hemisphere, humanity renews its quiet negotiation with a virus that refuses to be fully known. Australian health experts enter the 2026 flu season with cautious optimism — a better-matched vaccine, a new intranasal option for children, and hard lessons from 2025's deadliest outbreak in a century — yet they are careful to remind us that the influenza virus remains, at its core, unpredictable. The tools are sharper, but the humility required to face what cannot be controlled is as essential as the science itself.
- Australia is still recovering from its worst flu season in a hundred years, when the 'Super-K' H1N1 sub-type extended the outbreak far beyond normal bounds and overwhelmed the health system.
- Official case numbers from 2025 almost certainly undercount the true toll — countless people never sought testing or medical care, leaving the real burden of disease invisible in the data.
- The 2026 vaccine formulation has been updated with improved H1N1 and H3N2 component matching, and early global data suggests it performs well even against newly emerging variants.
- A long-awaited intranasal flu vaccine for children — already a cornerstone of childhood immunisation programs in the US, UK, and Canada — has finally been adapted for the Southern Hemisphere season and is now available.
- Despite the improvements, experts are firm: which strains will dominate, how severe the season will be, and how the virus will behave remain genuinely unknown until it unfolds.
Australia's 2025 flu season was the deadliest in a century, driven in part by a dominant sub-type dubbed Super-K that stretched the season far longer than usual and strained health resources across the country. As winter approaches again, experts are offering measured good news — but not without caveats.
Patrick Reading, who directs the WHO Collaborating Centre at the Doherty Institute, notes that the 2026 vaccine formulation has been improved, with better matching to both H1N1 and H3N2 strains based on current global circulation patterns. Early data suggests the updated vaccine performs well, even against newer variants. Still, Reading is careful to temper expectations: severity and dominant strains remain impossible to predict in advance. "We kind of have to wait and watch," he said.
Kristine Macartney of the University of Sydney adds another layer of sobering context — last year's record case numbers almost certainly underrepresent the true burden, since many people who fell ill never sought testing or medical attention. The official figures are, at best, a partial picture.
The most genuinely new development this season is the arrival of an intranasal flu vaccine for children. Already used successfully for years in the United States, Canada, and the United Kingdom — where it anchors the national childhood program — it has now been formulated for the Southern Hemisphere's seasonal calendar. Easier to administer than an injection and better tolerated by children, it may meaningfully lift vaccination rates in the age group most responsible for spreading flu through schools and households.
Whether a better-matched vaccine, a new delivery method for children, and the hard lessons of 2025 can together soften the 2026 season remains to be seen. Experts are united on one point: the virus still holds surprises, and vigilance cannot be substituted for certainty.
Australia's flu season this year has been mercifully quieter than 2025, when the country endured its deadliest influenza outbreak in a century. But as winter approaches, public health experts are already turning their attention to what comes next—and they're offering cautiously optimistic news about the vaccine that will protect Australians in 2026.
The 2025 season was brutal partly because of timing and partly because of a particular viral culprit. A dominant sub-type known as Super-K emerged and extended the flu season far longer than usual, stretching the health system's resources and catching many people off guard. Patrick Reading, who directs the WHO Collaborating Centre for Reference and Research on Influenza at the Doherty Institute, has been watching the viral landscape closely. He notes that this year's vaccine already incorporated changes to both the H1N1 and H3N2 components—the two main strains that typically circulate—and early data from around the world suggests the updated formulation works reasonably well, even against new variants that have started to emerge.
The 2026 vaccine, Reading says, should perform even better. The formulation being prepared is "a better match for the circulating viruses that we're expecting this winter." That's the kind of news that public health officials dream about: a vaccine that aligns well with what's actually circulating in the community. But Reading is careful not to oversell the forecast. "We cannot predict the severity, or which virus or viruses will predominate in the upcoming influenza season," he cautioned. "We kind of have to wait and watch."
That uncertainty is important context. Even with a better-matched vaccine, the actual impact of the 2026 season will depend on factors no one can fully control: which strains dominate, how transmissible they are, how many people actually get vaccinated, and how the virus behaves as it spreads through the population. Kristine Macartney, an influenza expert at the University of Sydney, points out another sobering reality about last year's record case numbers: they almost certainly undercount the true burden of disease. "There are many people who didn't go to the doctor, didn't get a test, didn't get notified," she said. The official figures capture only a fraction of the people who actually caught the flu.
But there is one genuinely new tool entering Australia's arsenal this winter: an intranasal flu vaccine for children. It's not new globally—the United States, Canada, and the United Kingdom have all been using it successfully for years, and in Britain it has become the cornerstone of the national childhood influenza program. What took time was manufacturing a version suited to the Southern Hemisphere's seasonal patterns. Now that it's available, Macartney sees it as a potential turning point. A nasal spray is easier to administer than an injection, and children often tolerate it better. More importantly, it may drive higher vaccination rates among the age group that tends to spread flu most efficiently through schools and households.
The 2026 season will test whether these improvements—a better-matched vaccine, new delivery options for children, and lessons learned from 2025's crisis—can bend the curve downward. But experts are clear: prediction ends where the virus begins. The coming months will require vigilance, vaccination, and the humility to acknowledge that influenza still holds surprises.
Citas Notables
The 2026 formulation is a better match for the circulating viruses we're expecting this winter— Patrick Reading, WHO Collaborating Centre for Reference and Research on Influenza
There are many people who didn't go to the doctor, didn't get a test, didn't get notified— Kristine Macartney, University of Sydney
La Conversación del Hearth Otra perspectiva de la historia
Why does a better vaccine match matter if we still can't predict severity?
Because it's the one variable we can actually control. A well-matched vaccine reduces transmission and hospitalizations even if the season turns out to be bad. It's not a guarantee—it's insurance.
The article mentions Super-K as a dominant sub-type. How much of last year's death toll came from that specific strain?
The source doesn't break down mortality by strain, but Super-K's emergence and the unusually long season are clearly linked. It suggests the virus had characteristics that made it harder to contain—either more transmissible or more able to evade immunity.
Macartney said the official case numbers are just the tip of the iceberg. How much worse could the real picture be?
She doesn't quantify it, but the implication is significant. For every person who got tested and reported, there were others who stayed home, recovered quietly, or never sought care. That's always true with flu, but it matters more when you're trying to understand what actually happened.
The intranasal vaccine for children—is that a silver bullet?
Not a silver bullet, but a meaningful shift. It removes friction from vaccination. Kids are more likely to accept a nasal spray than a needle, parents are more likely to follow through, and vaccinated children don't bring flu home to vulnerable adults. The UK made it central to their program for a reason.
What's the real risk for 2026?
That we become complacent. The vaccine is better, the tools are better, but Reading was explicit: we don't know what's coming. A new variant could emerge. Vaccination uptake could drop. The virus could surprise us again.